Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98419J206 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Morgan Stanley
13G/A
Amendment 4
|
0% |
8/7/2026
Event 7/31/2026
|
|
| Morgan Stanley | 0% | ||
| Morgan Stanley Investment Management Inc. | 0% | ||
|
Morgan Stanley
13G/A
Amendment 3
|
9.5% |
8/7/2026
Event 6/30/2026
|
|
| Morgan Stanley | 9.5% | ||
| Morgan Stanley Investment Management Inc. | 9.5% | ||
|
FMR LLC
13G/A
Amendment 7
|
0% |
8/7/2026
Event 7/31/2026
|
|
| FMR LLC | 0% | ||
| Abigail P. Johnson | 0% | ||
|
FMR LLC
13G/A
Amendment 6
|
9.1% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 9.1% | ||
| Abigail P. Johnson | 9.1% | ||
| Vanguard Capital Management LLC 13G/A Amendment 1 | 3.2% |
7/31/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 3.9% |
7/30/2026
Event 6/30/2026
|
|
|
Biotechnology Value Fund L P
13D/A
Amendment 15
|
0% |
7/16/2026
Event 7/14/2026
|
|
| Biotechnology Value Fund L P | 0% | ||
| BVF I GP LLC | 0% | ||
| Biotechnology Value Fund II LP | 0% | ||
| BVF II GP LLC | 0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 0% | ||
| BVF Partners L P/IL | 0% | ||
| BVF Inc/IL | 0% | ||
| Lampert Mark N | 0% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 14
|
43.3% |
5/18/2026
Event 5/14/2026
|
|
| Biotechnology Value Fund L P | 20.7% | ||
| BVF I GP LLC | 20.7% | ||
| Biotechnology Value Fund II LP | 15.8% | ||
| BVF II GP LLC | 15.8% | ||
| Biotechnology Value Trading Fund OS LP | 2.3% | ||
| BVF Partners OS Ltd. | 2.3% | ||
| BVF GP Holdings LLC | 36.5% | ||
| BVF Partners L P/IL | 43.3% | ||
| BVF Inc/IL | 43.3% | ||
| Lampert Mark N | 43.3% | ||
| Woodline Partners LP 13G | 5.4% |
5/15/2026
Event 3/31/2026
|
|
| Ligand Pharmaceuticals Inc 13D | 47.0% |
5/1/2026
Event 4/27/2026
|
|
| Vanguard Capital Management LLC 13G | 5.2% |
4/30/2026
Event 3/31/2026
|
|
|
Biotechnology Value Fund L P
13D/A
Amendment 13
|
21.4% |
4/29/2026
Event 4/27/2026
|
|
| Biotechnology Value Fund L P | 10.9% | ||
| BVF I GP LLC | 10.9% | ||
| Biotechnology Value Fund II LP | 10.5% | ||
| BVF II GP LLC | 10.5% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 21.4% | ||
| BVF Partners L P/IL | 21.4% | ||
| BVF Inc/IL | 21.4% | ||
| Lampert Mark N | 21.4% | ||
| BlackRock, Inc. 13G | 5.4% |
4/27/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
FMR LLC
13G/A
Amendment 5
|
10.2% |
3/6/2026
Event 2/27/2026
|
|
| FMR LLC | 10.2% | ||
| Abigail P. Johnson | 10.2% | ||
|
Morgan Stanley
13G/A
Amendment 2
|
13.7% |
2/12/2026
Event 12/31/2025
|
|
| Morgan Stanley | 13.7% | ||
| Morgan Stanley Investment Management Inc. | 13.7% | ||
|
FMR LLC
13G/A
Amendment 4
|
9.0% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 9.0% | ||
| Abigail P. Johnson | 9.0% | ||
| Vanguard Group Inc 13G | 5.3% |
7/29/2025
Event 6/30/2025
|
|
|
Morgan Stanley
13G/A
Amendment 1
|
12.7% |
6/6/2025
Event 5/30/2025
|
|
| Morgan Stanley | 12.7% | ||
| Morgan Stanley Investment Management Inc. | 12.7% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 12
|
21.6% |
5/20/2025
Event 5/16/2025
|
|
| Biotechnology Value Fund L P | 11.1% | ||
| BVF I GP LLC | 11.1% | ||
| Biotechnology Value Fund II LP | 10.6% | ||
| BVF II GP LLC | 10.6% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 21.6% | ||
| BVF Partners L P/IL | 21.6% | ||
| BVF Inc/IL | 21.6% | ||
| Lampert Mark N | 21.6% | ||
|
Morgan Stanley
13G
|
9.3% |
5/7/2025
Event 3/31/2025
|
|
| Morgan Stanley | 9.3% | ||
| Morgan Stanley Investment Management Inc. | 9.2% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 11
|
25.3% |
1/28/2025
Event 1/24/2025
|
|
| Biotechnology Value Fund L P | 12.3% | ||
| BVF I GP LLC | 12.3% | ||
| Biotechnology Value Fund II LP | 13.0% | ||
| BVF II GP LLC | 13.0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 25.3% | ||
| BVF Partners L P/IL | 25.3% | ||
| BVF Inc/IL | 25.3% | ||
| Lampert Mark N | 25.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 109 | 17.0 M | $724 M |
| 2026 Q1 | 89 | 9.99 M | $313 M |
| 2025 Q4 | 75 | 8.66 M | $231 M |
| 2025 Q3 | 75 | 8.33 M | $321 M |
| 2025 Q2 | 68 | 8.18 M | $206 M |
| 2025 Q1 | 68 | 7.85 M | $156 M |
| 2024 Q4 | 68 | 7.82 M | $205 M |
| 2024 Q3 | 71 | 7.70 M | $203 M |
| 2024 Q2 | 65 | 7.85 M | $185 M |
| 2024 Q1 | 64 | 7.93 M | $191 M |
| 2023 Q4 | 64 | 7.53 M | $139 M |
| 2023 Q3 | 56 | 7.64 M | $108 M |
| 2023 Q2 | 61 | 7.62 M | $139 M |
| 2023 Q1 | 53 | 7.05 M | $149 M |
| 2022 Q4 | 53 | 6.64 M | $122 M |
| 2022 Q3 | 48 | 6.28 M | $113 M |
| 2022 Q2 | 49 | 6.23 M | $139 M |
| 2022 Q1 | 56 | 6.37 M | $178 M |
| 2021 Q4 | 55 | 6.40 M | $133 M |
| 2021 Q3 | 50 | 6.33 M | $157 M |
| 2021 Q2 | 54 | 6.29 M | $214 M |
| 2021 Q1 | 63 | 6.37 M | $260 M |
| 2020 Q4 | 62 | 6.44 M | $284 M |
| 2020 Q3 | 57 | 6.32 M | $119 M |
| 2020 Q2 | 59 | 6.30 M | $124 M |
| 2020 Q1 | 51 | 4.81 M | $98.0 M |
| 2019 Q4 | 57 | 4.62 M | $126 M |
| 2019 Q3 | 48 | 3.27 M | $64.1 M |
| 2019 Q2 | 53 | 3.92 M | $58.2 M |
| 2019 Q1 | 52 | 4.17 M | $51.7 M |
| 2018 Q4 | 54 | 4.27 M | $53.8 M |
| 2018 Q3 | 63 | 3.61 M | $63.4 M |
| 2018 Q2 | 65 | 3.66 M | $76.4 M |
| 2018 Q1 | 59 | 3.40 M | $69.1 M |
| 2017 Q4 | 58 | 3.24 M | $115 M |
| 2017 Q3 | 35 | 2.73 M | $53.6 M |
| 2017 Q2 | 31 | 2.50 M | $17.5 M |
| 2017 Q1 | 35 | 2.37 M | $16.8 M |
| 2016 Q4 | 45 | 1.10 M | $4.63 M |
| 2016 Q3 | 2 | 30.7 k | $14.0 k |